Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8695820 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL16658797 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL7760880 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| Hexadecanoic Acid Propylamide SCHEMBL1457463 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL5173746 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL18812629 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL9097339 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL12460084 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL9964260 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL16658798 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | FAAH 4334/4885CASP2 4867/4885DNM1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.